January 11, 2013 -- The January 5th meeting in Chapel Hill was attended by representatives from the six surgical programs in NC: Brody School of Medicine, Carolinas Healthcare System, Duke University, New Hanover Medical Center, University of North Carolina, and Wake Forest School of Medicine.
April 22, 2013 -- A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.